Modulation of Epstein-Barr-Virus (EBV)-Associated Cancers by Co-Infections. 2023

Christian Münz
Viral Immunobiology, Institute of Experimental Immunology, University of Zürich, Winterthurerstrasse 190, 8057 Zürich, Switzerland.

The oncogenic and persistent Epstein Barr virus (EBV) is carried by more than 95% of the human adult population. While asymptomatic in most of these, EBV can cause a wide variety of malignancies of lymphoid or epithelial cell origin. Some of these are also associated with co-infections that either increase EBV-induced tumorigenesis or weaken its immune control. The respective pathogens include Kaposi-sarcoma-associated herpesvirus (KSHV), Plasmodium falciparum and human immunodeficiency virus (HIV). In this review, I will discuss the respective tumor entities and possible mechanisms by which co-infections increase the EBV-associated cancer burden. A better understanding of the underlying mechanisms could allow us to identify crucial features of EBV-associated malignancies and defects in their immune control. These could then be explored to develop therapies against the respective cancers by targeting EBV and/or the respective co-infections with pathogen-specific therapies or vaccinations.

UI MeSH Term Description Entries

Related Publications

Christian Münz
January 2017, International journal of biological sciences,
Christian Münz
November 1974, Acta medica Scandinavica,
Christian Münz
December 2012, Viruses,
Christian Münz
January 2012, Mediterranean journal of hematology and infectious diseases,
Christian Münz
June 2010, Nihon rinsho. Japanese journal of clinical medicine,
Christian Münz
December 1999, La Revue du praticien,
Christian Münz
July 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Christian Münz
March 2006, Nihon rinsho. Japanese journal of clinical medicine,
Christian Münz
July 1991, The Journal of infectious diseases,
Christian Münz
February 1987, Hawaii medical journal,
Copied contents to your clipboard!